Literature DB >> 33732999

Acid-Base Homeostasis During Vasopressin V2 Receptor Antagonist Treatment in Autosomal Dominant Polycystic Kidney Disease Patients.

Judith E Heida1, Ron T Gansevoort1, Esther Meijer1.   

Abstract

Entities:  

Year:  2021        PMID： 33732999      PMCID： PMC7938056          DOI： 10.1016/j.ekir.2020.12.021

Source DB:  PubMed          Journal:  Kidney Int Rep        ISSN： 2468-0249


× No keyword cloud information.
  9 in total

Review 1.  Vasopressin V1a and V1b receptors: from molecules to physiological systems.

Authors:  Taka-aki Koshimizu; Kazuaki Nakamura; Nobuaki Egashira; Masami Hiroyama; Hiroshi Nonoguchi; Akito Tanoue
Journal:  Physiol Rev       Date:  2012-10       Impact factor: 37.312

2.  Acute changes in osmolality and renin and respiratory control of arterial PCO2 and [H+].

Authors:  J W Anderson; I R Sarda; D B Jennings
Journal:  Respir Physiol       Date:  1990-04

3.  During acute hypercapnia vasopressin inhibits an angiotensin drive to ventilation in conscious dogs.

Authors:  J K Walker; D B Jennings
Journal:  J Appl Physiol (1985)       Date:  1995-09

4.  Vasopressin V1a receptors are present in the carotid body and contribute to the control of breathing in male Sprague-Dawley rats.

Authors:  Tymoteusz Żera; Jacek Przybylski; Tomasz Grygorowicz; Kaja Kasarełło; Martyna Podobińska; Dagmara Mirowska-Guzel; Agnieszka Cudnoch-Jędrzejewska
Journal:  Peptides       Date:  2018-03-07       Impact factor: 3.750

Review 5.  The role of venous blood gas in the emergency department: a systematic review and meta-analysis.

Authors:  Benjamin M Bloom; Johann Grundlingh; Jonathan P Bestwick; Tim Harris
Journal:  Eur J Emerg Med       Date:  2014-04       Impact factor: 2.799

6.  Vasopressin Increases Urinary Acidification via V1a Receptors in Collecting Duct Intercalated Cells.

Authors:  Torsten Giesecke; Nina Himmerkus; Jens Leipziger; Markus Bleich; Taka-Aki Koshimizu; Michael Fähling; Alina Smorodchenko; Julia Shpak; Carolin Knappe; Julian Isermann; Niklas Ayasse; Katsumasa Kawahara; Jan Schmoranzer; Niclas Gimber; Alexander Paliege; Sebastian Bachmann; Kerim Mutig
Journal:  J Am Soc Nephrol       Date:  2019-05-16       Impact factor: 10.121

7.  Short-term Effects of Tolvaptan in Individuals With Autosomal Dominant Polycystic Kidney Disease at Various Levels of Kidney Function.

Authors:  Wendy E Boertien; Esther Meijer; Paul E de Jong; Gert J ter Horst; Remco J Renken; Eric J van der Jagt; Peter Kappert; John Ouyang; Gerwin E Engels; Willem van Oeveren; Joachim Struck; Frank S Czerwiec; Dorothee Oberdhan; Holly B Krasa; Ron T Gansevoort
Journal:  Am J Kidney Dis       Date:  2015-01-15       Impact factor: 8.860

8.  Tolvaptan in patients with autosomal dominant polycystic kidney disease.

Authors:  Vicente E Torres; Arlene B Chapman; Olivier Devuyst; Ron T Gansevoort; Jared J Grantham; Eiji Higashihara; Ronald D Perrone; Holly B Krasa; John Ouyang; Frank S Czerwiec
Journal:  N Engl J Med       Date:  2012-11-03       Impact factor: 91.245

Review 9.  Tolvaptan, an orally active vasopressin V(2)-receptor antagonist - pharmacology and clinical trials.

Authors:  Toshiki Miyazaki; Hiroyuki Fujiki; Yoshitaka Yamamura; Shigeki Nakamura; Toyoki Mori
Journal:  Cardiovasc Drug Rev       Date:  2007
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.